AZD-7325 is a novel, potent and selective GABAA(α2/3) receptor modulator, used for treatment of generalized anxiety disorder.

Etifoxine (HOE-36801) and etafenoxine, is a non-benzodiazepine GABAergic anxiolytic and anticonvulsant drug developed by Hoechst in the 1960s, and sold in approximately 40 countries for anxiety disorders, without the sedation and ataxia associated with benzodiazepine drugs.

Tiagabine HCl (NNC-05-0328; NO-05-0328; NO329; NNC-050328; NO 329; trade name Gabitril), the hydrochloride salt of tiagabine, is an marketed anticonvulsant acting as a selective GABA (gamma-aminobutyric acid) reuptake inhibitor, may also be used for the treatment of panic disorders.

Fluralaner (A-1443; AH-252723; trade name: Bravecto) is an orally bioavailable and systemic insecticide and acaricide approved by the US Food and Drug Administration (FDA) under the trade name Bravecto for flea treatment in dogs in May 2014.

Afloqualone (HQ-495; HQ495; HQ 495) is a centrally acting muscle relaxant and an agonist of GABA receptor with sedative and muscle-relaxant effects.

Lorediplon, a nonbenzodiazepine of the pyrazolopyrimidine family, is a non-benzodiazepine drug acting as a GABAA receptor modulator, differentially active at the alpha1-subunit, associated with promoting sleep.